Antagonist CD40 monoclonal antibodies and uses thereof
Isolated antibodies with defined CDRs and modified Fc domains that reduce Fc-gamma receptor binding effectively antagonize CD40 activity, addressing the issue of agonist activity in existing antibodies and providing a therapeutic solution for autoimmune and inflammatory diseases.
Patent Information
- Application Number
- JP2023072027
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-11-19
- Filing Date
- 2023-04-26
- Publication Date
- 2024-11-20
- Estimated Expiration
- 2039-11-18
AI Technical Summary
Existing monoclonal antibodies targeting CD40 can exhibit agonist activity, leading to undesirable T cell responses in autoimmune and inflammatory diseases, and there is a need for antibodies that specifically bind CD40 without activating it.
Development of isolated antibodies with specific heavy and light chain variable regions, including defined complementarity determining regions (CDRs) and modified Fc domains, which reduce binding to Fc-gamma receptors, thereby minimizing agonist activity and potential toxicity.
The antibodies effectively antagonize CD40 activity, reducing unwanted immune responses and minimizing toxicity, making them suitable for treating autoimmune and inflammatory diseases.
Smart Images

Figure 0007587629000036 
Figure 0007587629000037 
Figure 0007587629000038
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Patent Application No. 62 / 769,514, filed November 19, 2018, which is incorporated herein in its entirety for all purposes.
[0002] Sequence Listing This application contains a Sequence Listing submitted electronically in ASCII format, which is incorporated herein by reference in its entirety. The ASCII copy created on November 13, 2019 has the file name 200896-0015-00-WO-592417_SL.txt and is 170,111 bytes in size.
[0003] The present disclosure provides an antibody that binds to CD40. The antibody polypeptide binds to CD40 but does not exhibit CD40 agonist activity. The antibody comprises a modified IgG1 Fc domain and may exhibit minimal activation of immature dendritic cells. Compositions comprising the antibody, methods of use for treating diseases involving CD40 activity, and use in the preparation of medicaments for treating diseases associated with CD40 activity are provided. [Background technology]
[0004] CD40 is a costimulatory molecule belonging to the tumor necrosis factor (TNF) receptor superfamily that is presented on antigen-presenting cells (APCs), including dendritic cells, B cells, and macrophages. APCs bind CD40 to its ligand, CD154 (CD40L), and thus become T cells. H Upon binding to the surface of cells, APCs are activated. Activation of APCs via CD40 is involved in various immune responses, including cytokine production, increased costimulatory molecules (e.g., CD86), and enhanced antigen presentation and proliferation of B cells. CD40 can also be expressed on endothelial cells, smooth muscle cells, fibroblasts, and epithelial cells.
[0005] Activation of CD40 is also involved in various undesirable T cell responses, for example related to autoimmunity, transplant rejection or allergic reactions. One strategy to control undesirable T cell responses is to target CD40 with antagonistic antibodies. For example, the monoclonal antibody HCD122 (Lucatumumab), formerly known as Chiron1212, is currently in clinical trials for the treatment of certain CD40-mediated inflammatory diseases. Hypertext Transfer Protocol on the Internet: clinicaltrialsfeeds.org / clinical-trials / show / NCT01275209 (last updated January 11, 2011) “Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40 + See, "Rituximab-Refractory Follicular Lymphoma", Clinical Trials Feeds. However, monoclonal antibodies can exhibit agonistic activity. For example, the utility of the anti-CD40 antibody Chi220 is limited by its weak stimulatory capacity. See Adams, et al., "Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival" J. Immunol. 174: 542-50 (2005). Summary of the Invention
[0006] In a first embodiment, the invention provides an isolated antibody, or an antigen-binding portion thereof, that specifically binds to human CD40, wherein the antibody comprises a first polypeptide portion comprising a heavy chain variable region and a second polypeptide portion comprising a light chain variable region, wherein: The heavy chain variable region comprises one of: (i) a CDR1 comprising SYWMH (SEQ ID NO:1), a CDR2 comprising QINPTTGRSQYNEKFKT (SEQ ID NO:2), and a CDR3 comprising WGLQPFAY (SEQ ID NO:3); and (ii) a CDR1 comprising SYWMH (SEQ ID NO:1), a CDR2 comprising QINPSQGRSQYNEKFKT (SEQ ID NO:12), and a CDR3 comprising WGLQPFAY (SEQ ID NO:3); and The light chain variable region comprises CDR1 comprising KASQDVSTAVA (SEQ ID NO:7), CDR2 comprising SASYRYT (SEQ ID NO:8), and CDR3 comprising QQHYSTPWT (SEQ ID NO:9).
[0007] The invention further provides an isolated antibody, or an antigen-binding portion thereof, that specifically binds to human CD40, wherein the antibody comprises a first polypeptide portion comprising a heavy chain variable region and a second polypeptide portion comprising a light chain variable region, wherein: The heavy chain variable region comprises one of (i) CDR1 consisting of SYWMH (SEQ ID NO: 1), CDR2 consisting of QINPTTGRSQYNEKFKT (SEQ ID NO: 2), and CDR3 consisting of WGLQPFAY (SEQ ID NO: 3); and (ii) CDR1 consisting of SYWMH (SEQ ID NO: 1), CDR2 consisting of QINPSQGRSQYNEKFKT (SEQ ID NO: 12), and CDR3 consisting of WGLQPFAY (SEQ ID NO: 3); and The light chain variable region comprises CDR1 consisting of KASQDVSTAVA (SEQ ID NO: 7), CDR2 consisting of SASYRYT (SEQ ID NO: 8), and CDR3 consisting of QQHYSTPWT (SEQ ID NO: 9).
[0008] The invention further provides an isolated antibody, or an antigen-binding portion thereof, that specifically binds to human CD40, wherein the antibody comprises a first polypeptide portion comprising a heavy chain variable region and a second polypeptide portion comprising a light chain variable region, wherein: The heavy chain variable region comprises CDR1 consisting of SYWMH (SEQ ID NO: 1), CDR2 consisting of QINPTTGRSQYNEKFKT (SEQ ID NO: 2), and CDR3 consisting of WGLQPFAY (SEQ ID NO: 3); and The light chain variable region comprises CDR1 consisting of KASQDVSTAVA (SEQ ID NO: 7), CDR2 consisting of SASYRYT (SEQ ID NO: 8), and CDR3 consisting of QQHYSTPWT (SEQ ID NO: 9).
[0009] The invention further provides an isolated antibody, or an antigen-binding portion thereof, that specifically binds to human CD40, wherein the antibody comprises a first polypeptide portion comprising a heavy chain variable region and a second polypeptide portion comprising a light chain variable region, wherein: The heavy chain variable region has the amino acid sequence QVQLVQSGAEVKKPGSSVKVSCKASGYAFT SYWMH WVRQAPGQGLEWMG QINPTTGRSQYNEKFKT RVTITADKSTSTAYMELSSLRSEDTAVYYCAR WGLQPFAY WGQGTLVTVSS (SEQ ID NO: 4), and the light chain variable region has the amino acid sequence DIQMTQSPSFLSASVGDRVTITC KASQDVSTAVA WYQQKPGKAPKLLIY SASYRYT GVPSRFSGSGSGTDFLTISSLQPEDFATYYC QQHYSTPWT FGGGTKVEIK (SEQ ID NO: 10).
[0010] The present invention further provides an isolated antibody or antigen-binding portion thereof that specifically binds to human CD40, wherein the antibody comprises a first polypeptide portion comprising a heavy chain variable region and a second polypeptide portion comprising a light chain variable region, wherein the heavy chain variable region has the amino acid sequence QVQLVQSGAEVKKPGSSVKVSCKASGYAFT SYWMH WVRQAPGQGLEWMG QINPSQGRSQYNEKFKT RVTITADKSTSTAYMELSSLRSEDTAVYYCAR WGLQPFAY WGQGTLVTVSS (SEQ ID NO: 13), and the light chain variable region has the amino acid sequence EIVMTQSPATLSVSPGERATLSC KASQDVSTAVA WYQQKPGQAPRLLIY SASYRYT GIPARFSGSGSGTEFTLTISSLQSEDFAVYYC QQHYSTPWT FGGGTKVEIK (SEQ ID NO: 16).
[0011] The present invention further provides an isolated antibody or antigen-binding portion thereof that specifically binds to human CD40, wherein the antibody comprises a first polypeptide portion comprising a heavy chain variable region and a second polypeptide portion comprising a light chain variable region, wherein the heavy chain variable region has the amino acid sequence QVQLVQSGAEVKKPGSSVKVSCKASGYAFT SYWMH WVRQAPGQGLEWMG QINPTTGRSQYNEKFKT RVTITADKSTSTAYMELSSLRSEDTAVYYCAR WGLQPFAY WGQGTLVTVSS (SEQ ID NO: 4), and the light chain variable region has the amino acid sequence EIVMTQSPATLSVSPGERATLSC KASQDVSTAVA WYQQKPGQAPRLLIY SASYRYT GIPARFSGSGSGTEFTLTISSLQSEDFAVYYC QQHYSTPWT FGGGTKVEIK (SEQ ID NO: 16).
[0012] In certain embodiments, the isolated antibody or antigen-binding portion thereof comprises a first polypeptide portion comprising a human heavy chain constant region; and a second polypeptide portion comprising a human light chain constant region. The isolated antibody or antigen-binding portion thereof described herein may comprise a human IgG1 Fc domain comprising either (1) a mutation at Kabat position 238 that reduces binding to Fc-gamma-receptors (FcγR), where proline 238 (P238) is mutated to one residue selected from the group consisting of lysine, serine, alanine, arginine, tryptophan, and where the antibody or antigen-binding portion thereof has reduced FcγR binding; or (2) an alanine substitution at Kabat position 297.
[0013] The isolated antibody or antigen-binding portion thereof described herein may comprise a human IgG1 Fc domain comprising a mutation at Kabat position 238 that reduces binding to Fc-gamma-receptors (FcγR), where proline 238 (P238) is mutated to one residue selected from the group consisting of lysine, serine, alanine, arginine, tryptophan, and wherein the antibody or antigen-binding portion thereof has reduced FcγR binding. In a specific embodiment, P238 is mutated to lysine.
[0014] The isolated antibody or antigen-binding portion thereof described herein may comprise an Fc domain comprising an amino acid sequence selected from the following: EPKSCDKTHTCPPCPAPELLGG K SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 22; IgG1-P238K (-C-terminal lysine)), EPKSCDKTHTCPPCPAPELLGG K SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 23; IgG1-P238K), [ka] EPKSCDKTHTCPPCPAPELLGG KSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 26; IgG1f-P238K (-C-terminal lysine)), EPKSCDKTHTCPPCPAPELLGG K SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 27; IgG1f-P238K), ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGG K SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 28; CH1-IgG1f-P238K (-C-terminal lysine)), or ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGG K SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 29; CH1-IgG1f-P238K).
[0015] In certain embodiments, the isolated antibody or antigen-binding portion thereof described herein comprises: (1) a Kabat mutation at position 238 that reduces binding to Fc-gamma-receptors (FcγR), wherein the proline at position 238 (P238) is mutated to one residue selected from the group consisting of lysine, serine, alanine, arginine, and tryptophan, and wherein the antibody or antigen-binding site thereof has reduced FcγR binding; or (2) a human IgG1 Fc domain, comprising any one of the following: an alanine substitution at position 297 of Kabat; and a heavy chain variable region comprising a CDR1 comprising SYWMH (SEQ ID NO: 1), a CDR2 comprising QINPTTGRSQYNEKFKT (SEQ ID NO: 2), and a CDR3 comprising WGLQPFAY (SEQ ID NO: 3); and a light chain variable region comprising a CDR1 comprising KASQDVSTAVA (SEQ ID NO: 7), a CDR2 comprising SASYRYT (SEQ ID NO: 8), and a CDR3 comprising QQHYSTPWT (SEQ ID NO: 9).
[0016] The isolated antibody and antigen-binding portion thereof may comprise a human IgG1 Fc domain comprising the amino acid sequence of SEQ ID NO:22 or SEQ ID NO:23.
[0017] In some embodiments of the isolated antibodies or antigen-binding portions thereof described herein, the first polypeptide portion comprises or consists of an amino acid sequence selected from the group consisting of: [ka] , and [ka] ; and The second polypeptide portion comprises or consists of the following amino acid sequence: DIQMTQSPSFLSASVGDRVTITC KASQDVSTAVA WYQQKPGKAPKLLIY SASYRYT GVPSRFSGSGSGTDFLTISSLQPEDFATYYC QQHYSTPWT FGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 11; LC_Y12XX-hz28-CL).
[0018] In some embodiments of the isolated antibodies or antigen-binding portions thereof described herein, the first polypeptide portion comprises or consists of the following amino acid sequence: [ka] and The second polypeptide portion comprises or consists of the following amino acid sequence: [ka]
[0019] In certain embodiments, the isolated antibody or antigen-binding portion thereof described herein comprises a human IgG1 Fc domain comprising a human IgG1 Fc domain comprising an alanine substitution at position 297 of Kabat.
[0020] The isolated antibodies or antigen-binding portions thereof described herein may antagonize the activity of CD40. The isolated antibodies or antigen-binding portions thereof described herein may be chimeric antibodies. The isolated antibodies or antigen-binding portions thereof described herein may be humanized antibodies. The isolated antibodies or antigen-binding portions thereof described herein may comprise a human heavy chain constant region and a human light chain constant region.
[0021] The antibody and antigen-binding portion thereof disclosed herein is an antigen-binding portion selected from the group consisting of Fv, Fab, F(ab')2, Fab', dsFv, scFv, sc(Fv)2, bibody, and scFv-Fc. The antibody and antigen-binding portion thereof disclosed herein is an scFv-Fc.
[0022] The antibodies and antigen-binding portions thereof disclosed herein may be linked to a therapeutic agent.
[0023] The antibodies and antigen-binding sites thereof disclosed herein may be linked to a second functional moiety that has a binding specificity different from that of the antibody and antigen-binding site.
[0024] The antibodies and antigen-binding portions thereof disclosed herein may further comprise additional moieties.
[0025] Nucleic acid molecules encoding isolated antibodies or antigen-binding portions thereof are disclosed herein. Expression vectors comprising the nucleic acid molecules are disclosed herein. Cells transformed with the expression vectors are also contemplated. A method for preparing an anti-human CD40 antibody or antigen-binding portion thereof, comprising: a) expressing the antibody, or antigen-binding portion thereof, in a cell transformed with an expression vector comprising a nucleic acid molecule encoding the antibody, or antigen-binding portion thereof, disclosed herein; and b) isolating the antibody or an antigen-binding portion thereof from the cell; Also disclosed is a method comprising:
[0026] Also provided is a pharmaceutical composition comprising: a) an antibody or antigen-binding portion thereof disclosed herein; and b) a pharma- ceutical acceptable carrier.
[0027] Methods of treating or preventing an immune response in a subject are provided, comprising administering to a subject an antibody disclosed herein, or an antigen-binding portion thereof. Methods of treating or preventing an autoimmune or inflammatory disease in a subject are also provided, comprising administering to a subject an antibody disclosed herein, or an antigen-binding portion thereof. Optionally, the antibody, or an antigen-binding portion thereof, is administered together with an immunosuppressant / immunomodulatory agent and / or an anti-inflammatory agent. Administration may be simultaneous or sequential. An exemplary agent is a CTLA4 mutant molecule, such as L104EA29Y-Ig (Belatacept). In such methods of treating or preventing an immune response in a subject, and in such methods of treating or preventing an autoimmune or inflammatory disease in a subject, preferably the subject has a disease selected from the group consisting of: Addison's disease, allergies, anaphylaxis, ankylosing spondylitis, asthma, arteriosclerosis, atopic allergies, autoimmune diseases of the ear, autoimmune diseases of the eye, autoimmune hepatitis, autoimmune parotitis, bronchial asthma, coronary heart disease, Crohn's disease, diabetes, epididymis, and the like. inflammatory bowel disease, immune reactions to genetically modified drugs (e.g., factor VII in hemophilia patients), lupus nephritis, systemic lupus erythematosus, multiple sclerosis, myasthenia gravis, pemphigus, psoriasis, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome, spondyloarthropathy, thyroiditis, transplant rejection, vasculitis, and ulcerative colitis.
[0028] Also contemplated are the antibodies or antigen-binding portions thereof disclosed herein for use as pharmaceuticals.Furthermore, contemplated are the antibodies or antigen-binding portions thereof disclosed herein, or pharmaceuticals comprising the antibodies or antigen-binding portions thereof, for use in treatment in a subject in need thereof.Furthermore, contemplated are therapeutically effective amounts of the antibodies or antigen-binding portions thereof disclosed herein for use in treating or preventing an immune response, for administration to a patient in need thereof. [Brief description of the drawings]
[0029] [Figure 1-1] FIG. 1, comprising FIGS. 1A-1D, shows SPR sensorgram data of antibody binding to human FcγR. FIG. 1A shows data for a control antibody, control IgG1. FIG. 1B shows data for Y12XX-hx28-IgG1-P238K, control IgG1. FIG. 1C shows data for a control antibody, antibody B. FIG. 1D is a table summarizing KD values for antibody / FcγR interactions. KD values were obtained from either 1:1 Langmuir fits (hCD64) or 1:1 steady-state fits (hCD32a-H131, hCD32a-R131, hCD32b, hCD16a-V158, and hCD16a-F158). [Figure 1-2] Same as above.
[0030] [Figure 2-1]FIG. 2, including FIGS. 2A-2C, shows activation data of iDCs treated with humanized Y12XX or control antibodies with or without CD32a-expressing CHO cells. Increase in IL-6 (Interleukin-6) from cell culture medium and expression of cell surface markers represented by flow cytometry fluorescence mean values stained with anti-CD86 and anti-CD54 antibodies were assessed. FIG. 2A shows IL-6 data. FIG. 2B shows CD86 data. FIG. 2C shows CD54 data. Mean fluorescence intensity (MFI) was measured and shown on the Y-axis for both FIG. 2B and FIG. 2C. Each symbol represents data for iDCs from an individual donor. Y12XX-hz42-P238K was tested on cells from four donors, Y12XX-hz40-P238K was tested on cells from six donors, and Y12XX-hz28-P238K was tested on cells from ten donors. Antibody concentrations are shown in μg / ml (10, 30, or 100 μg / ml). Inclusion of CHO-32a cells in the assay indicates that they mediate cross-linking or clustering via FcγR. Ly6-IgG was used as a negative control. Partial CD40 agonists 2141 and BMS986090-100 were used as positive controls. [Figure 2-2] Same as above. [Figure 2-3] Same as above.
[0031] [Diagram 3] Figure 3, comprising Figures 3A and 3B, shows exemplary data from complement dependent cytotoxicity (CDC) analysis of humanized Y12XX, CD40, and control antibodies. CDC assays were performed twice. Freshly thawed human complement serum was used in the second assay. Figure 3A shows data from the first replicate of the assay, and Figure 3B shows data from the second replicate of the assay.
[0032] [Figure 4]Figure 4, comprising Figure 4A and Figure 4B, shows exemplary data obtained from antibody-dependent cellular phagocytosis (ADCP) analysis of humanized Y12XX antibodies or control antibodies using CD14+ monocytes from two different donors as effector cells. Figure 4A shows data obtained using CD14+ monocytes from donor #8 as effector cells. Figure 4B shows data obtained using CD14+ monocytes from donor #65 as effector cells.
[0033] [Diagram 5] Figure 5, comprising Figures 5A and 5B, shows exemplary data obtained from antibody-dependent cellular cytotoxicity (ADCC) analysis of humanized Y12XX or control antibodies using NK cells from two different donors as effector cells. Figure 5A shows data obtained using NK cells from donor #38 as effector cells. Figure 5B shows data obtained using NK cells from donor #55 as effector cells.
[0034] [Figure 6-1] Figure 6, comprising Figures 6A, 6B, 6C, and 6D, shows data from an assay designed to assess NF-κB / AP-1-induced SEAP activity in Ramos Blues cells upon stimulation with different anti-CD40 antibodies. Representative results from three independent studies of the activity of CD40 mAbs are shown in Figures 6A and 6B. Figures 6C and 6D show data for the positive control, CD40L-IZ. AIMV: AIM V™ Medium (1x) (Thermo Fisher Scientific, Waltham, MA). [Figure 6-2] Same as above. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0035] The present disclosure relates to anti-CD40 antibodies, and in particular antagonistic anti-CD40 antibodies. For therapeutic targets such as CD40, cross-linking of anti-CD40 antibodies via FcγRs can potentially result in unwanted agonistic signaling and potential toxicity. The present disclosure also describes antagonistic anti-CD40 antibodies that have reduced association with "low affinity" FcγRs: hCD32a / FcγRIIa, hCD32b / FcγRIIb and hCD16a / FcγRIIIa, and also with "high affinity" FcγRhCD64. Reduced association with low affinity FcγRs is expected to reduce the likelihood of unwanted agonistic signaling and potential toxicity.
[0036] Definitions and Abbreviations Further abbreviations and definitions are provided below. [Table A]
[0037] In accordance with this detailed description, the following abbreviations and definitions apply. It should be noted that as used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "an antibody" includes a plurality of such antibodies, and reference to "the dosage" includes reference to one or more dosages and equivalents known to those skilled in the art.
[0038] As used herein, the term "about" is understood by those of ordinary skill in the art and will vary to some extent depending on the context in which it is used. In general, "about" encompasses a range of values of plus / minus 10% of the referenced value, unless otherwise indicated herein.
[0039] It is understood that any and all whole integers or partial integers between the set ranges are included herein.
[0040] CD40 is also known and referred to as B-cell surface antigen CD40, Bp50, CD40L receptor, CDw40, CDW40, MGC9013, p50, TNFRSF5, and tumor necrosis factor receptor superfamily member 5. "Human CD40" refers to CD40 comprising the following amino acid sequence: MVRLPLQCVL WGCLLTAVHP EPPTACREKQ YLINSQCCSL CQPGQKLVSD CTEFTETECL PCGESEFLDT WNRETHCHQH KYCDPNLGLR VQQKGTSETD TICTCEEGWH CTSEACESCV LHRSCSPGFG VKQIATGVSD TICEPCPVGF FSNVSSAFEK CHPWTSCETK DLVVQQAGTN KTDVVCGPQD RLRALVVIPI IFGILFAILL VLVFIKKVAK KPTNKAPHPK QEPQEINFPD DLPGSNTAAP VQETLHGCQP VTQEDGKESR ISVQERQ (SEQ ID NO: 20).
[0041] As used herein, the term "variable domain" refers to an immunoglobulin variable domain as defined in Kabat, et al., Sequences of Immunological Interest, 5th ed., US Dept. Health & Human Services, Washington, DC (1991). Numbering and positioning of CDR amino acid residues within a variable domain follow the well-known Kabat numbering convention. VH, "variable heavy chain" and "variable heavy chain domain" refer to the variable domain of a heavy chain. VL, "variable light chain" and "variable light chain domain" refer to the variable domain of a light chain.
[0042] The term "human" when applied to an antibody means that the antibody has sequences derived from a human immunoglobulin, e.g., FR and / or CH domains. A sequence is "derived from" a human immunoglobulin coding sequence if the sequence is either: (a) isolated from a human individual or from a cell or cell line obtained from a human individual; (b) isolated from a library of cloned human antibody gene sequences or human antibody variable domain sequences; or (c) diversified by mutation and selection from one or more of the above polypeptides.
[0043] As used herein, an "isolated" compound means that the compound is removed from at least one component with which it is naturally associated.
[0044] The anti-CD40 antibodies of the disclosure comprise a variable heavy chain and a variable light chain, each of which contains three complementarity determining regions (CDRs) and four framework regions (FRs), arranged from amino-terminus to carboxyl-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The CDRs contain most of the residues that form specific interactions with the antigen and are primarily responsible for antigen recognition.
[0045] The anti-CD40 antibodies of the present disclosure may include the CDRs of humanized antibodies Y12XX-hz28 (Vh-hz14; Vk-hz2), Y12XX-hz40 (Vh-hz12; Vk-hz3), or Y12XX-hz42 (Vh-hz14; Vk-hz3). An overview of the amino acid sequences of the heavy and light chain variable regions is provided in Table 1. The table includes the short and long names and sequence identifiers for each amino acid sequence. [Table 1]
[0046] In certain embodiments, the anti-CD40 antibodies of the present disclosure comprise the CDRs of humanized antibody Y12XX-hz28 (Vh-hz14; Vk-hz2). The amino acid sequence of Y12XX-hz28 is detailed in Table 2. [Table 2-1] [Table 2-2]
[0047] In certain embodiments, an anti-CD40 antibody of the disclosure comprises the CDRs of humanized antibody Y12XX-hz40 (Vh-hz12; Vk-hz3). The amino acid sequence of Y12XX-hz40 is shown in Table 3. [Table 3-1] [Table 3-2]
[0048] In certain embodiments, the anti-CD40 antibodies of the present disclosure comprise the CDRs of humanized antibody Y12XX-hz42 (Vh-hz14; Vk-hz3). The amino acid sequence of Y12XX-hz42 is detailed in Table 4. [Table 4-1] [Table 4-2]
[0049] In one embodiment, the antibody of the disclosure may comprise the amino acid sequences of the CDR1, CDR2, and CDR3 regions of the humanized Y12XX-hz28 variable heavy and light chain sequences (e.g., SEQ ID NOs: 4 and 10, respectively). H 3 and V L For example, the variable heavy chain CDRs 1-3 contain SYWMH (SEQ ID NO:1), QINPTTGRSQYNEKFKT (SEQ ID NO:2), and WGLQPFAY (SEQ ID NO:3), respectively, and the variable light chain CDRs 1-3 contain KASQDVSTAVA (SEQ ID NO:7), SASYRYT (SEQ ID NO:8), and QQHYSTPWT (SEQ ID NO:9), respectively.
[0050] In one embodiment, the antibody of the disclosure may comprise the amino acid sequences of CDR1, CDR2, and CDR3 of the humanized Y12XX-hz40 variable heavy and light chain sequences (e.g., SEQ ID NOs: 13 and 16, respectively). H 3 and V L For example, the variable heavy chain CDRs 1-3 contain SYWMH (SEQ ID NO:1), QINPSQGRSQYNEKFKT (SEQ ID NO:12), and WGLQPFAY (SEQ ID NO:3), respectively, and the variable light chain CDRs 1-3 contain KASQDVSTAVA (SEQ ID NO:7), SASYRYT (SEQ ID NO:8), and QQHYSTPWT (SEQ ID NO:9), respectively.
[0051] In one embodiment, the antibody of the disclosure may comprise the amino acid sequences of CDR1, CDR2, and CDR3 of the humanized Y12XX-hz42 variable heavy and light chain sequences (e.g., SEQ ID NOs: 4 and 16, respectively). H 3 and V LFor example, the variable heavy chain CDRs 1-3 contain SYWMH (SEQ ID NO:1), QINPTTGRSQYNEKFKT (SEQ ID NO:2), and WGLQPFAY (SEQ ID NO:3), respectively, and the variable light chain CDRs 1-3 contain KASQDVSTAVA (SEQ ID NO:7), SASYRYT (SEQ ID NO:8), and QQHYSTPWT (SEQ ID NO:9), respectively.
[0052] An "antibody" shall include, but is not limited to, an immunoglobulin that specifically binds an antigen and comprises at least two heavy (H) chains and two light (L) chains, or antigen-binding sites thereof, interconnected by disulfide bonds. Each H chain comprises a heavy chain variable region (herein referred to as V H The heavy chain constant region is made up of three constant domains, C H1 , C H2 , and C H3 Each light chain comprises a light chain variable region (referred to herein as V L The light chain constant region comprises one constant domain, C L Includes: V H and V L The region can be further divided into regions of hypervariability called complementarity determining regions (CDRs) interspersed with regions of relative conservedness called framework regions (FRs). H and V L contains three CDRs and four FRs, arranged from amino terminus to carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain a binding domain that interacts with an antigen.
[0053] An "antigen-binding site" of an Ab (also called an "antigen-binding fragment") or an antigen-binding portion thereof refers to one or more sequences of an antibody (full-length or a fragment of a full-length antibody) that retain the ability to specifically bind to the antigen to which the full-length antibody binds. Examples of antigen-binding fragments include Fab, F(ab')2, scFv (single-chain fragment variable), Fab', dsFv, sc(Fv)2, and scFv-Fc.
[0054] A "humanized" antibody refers to an Ab in which some, most, or all of the amino acid sequence outside the CDR domains of a non-human Ab has been replaced with the corresponding amino acid sequence from a human immunoglobulin. In one embodiment of humanizing an Ab, some, most, or all of the amino acid sequence outside the CDR domains is replaced with amino acid sequence from a human immunoglobulin, while some, most, or all of the amino acid sequence inside one or more CDR regions remains unchanged. Small additions, deletions, insertions, substitutions, or modifications of amino acids are permissible as long as they do not impair the Ab's ability to bind to its specific antigen. A "humanized" Ab retains close antigen specificity to the original Ab.
[0055] A "chimeric antibody" refers to an Ab whose variable regions are derived from one species and whose constant regions are derived from another species, e.g., the variable regions are derived from a murine Ab and the constant regions are derived from a human Ab.
[0056] As used herein, "specific binding" refers to binding of an antibody to an antigen with a dissociation constant (Kd) of about 1 μM or less, as measured, for example, by surface plasmon resonance (SPR). Suitable assay systems include the BIAcore. (商標) (GE Healthcare Life Sciences, Marlborough, MA) Surface Plasmon Resonance System, and BIAcore (商標) Includes dynamic evaluation software (e.g. version 2.1).
[0057] The binding of the antibody to CD40 antagonizes at least one activity of CD40. "CD40 activity" includes, but is not limited to, activation of T cells (e.g., induction of T cell proliferation or cytokine secretion), activation of macrophages (e.g., induction of reactive oxygen species and nitric oxide in macrophages), and activation of B cells (e.g., B cell proliferation, antibody isotype switching, or differentiation into plasma cells). CD40 activities may be mediated by interactions with other molecules. "CD40 activity" includes functional interactions between CD40 and the following molecules, whose Uniprot identification numbers are listed in parentheses: CALR (P27797); ERP44 (Q9BS26); FBL (P22087); POLR2H (P52434); RFC5 (P40937); SGK1 (O00141); SLC30A7 (Q8NEW0); SLC39A7 (Q92504); TRAF2 (Q5T1L5); TRAF3 (Q13114); TRAF6 (Q9Y4K3); TXN (Q5T937); UGGT1 (Q9NYU2); and USP15 (Q9Y4E8).
[0058] For example, CD40 "activity" includes interaction with TRAF2. CD40 / TRAF2 interaction activates NF-κB and JNK. See Davies et al., Mol. Cell Biol. 25:9806-19 (2005). Thus, this CD40 activity can be determined by CD40-dependent cellular NF-κB and JNK activation relative to a reference.
[0059] As used herein, the terms "activation", "activating" and "activated" refer to an increase in measurable CD40 activity of at least 10% compared to a reference, for example, an increase of at least 10%, 25%, 50%, 75%, or 100% or more. CD40 activity is "antagonized" when CD40 activity is reduced by at least 10% compared to the absence of antagonist, in exemplary embodiments by at least about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 97%, or 100% (i.e., no activity is detected). For example, an antibody may antagonize some or all of CD40 activity without activating CD40. For example, the antibody may not activate B cell proliferation. The antibody may not activate cytokine secretion by the T cell, where the cytokine is at least one cytokine selected from the group consisting of IL-2, IL-6, IL-10, IL-13, TNF-α, and INF-γ.
[0060] A variable domain may contain one or more framework regions (FR) that have the same amino acid sequence as a framework region encoded by a corresponding human germline antibody gene segment. Preferred framework sequences for use in the antibodies described herein are those that are structurally close to the framework sequences used in the antibodies described herein. H CDR1, 2, and 3 sequences, and V L CDR1, 2, and 3 sequences can be fused into framework regions that have sequences identical to those found in the germline immunoglobulin gene from which the framework sequences are derived, or the CDR sequences can be fused to framework regions that contain up to 20, preferably conservative, amino acid substitutions compared to the germline sequence. For example, it has been found that in certain instances, mutation of residues in the framework regions is beneficial to maintain or enhance the antigen-binding ability of the antibody. (See, e.g., U.S. Patent Nos. 5,530,101; 5,585,089; 5,693,762; and 6,180,370 to Queen et al.).
[0061] Exemplary framework regions include, but are not limited to, those in Tables 5 and 6 below. [Table 5] [Table 6]
[0062] The variant variable domain may differ from the variable domain of the humanized Y12XX-28, Y12XX-hz40, or Y12XX-hz42 sequence by up to 10 amino acids, or any integer value therebetween, where the variant variable domain specifically binds to CD40. Alternatively, the variant variable domain may have at least 90% sequence identity (e.g., at least 92%, 95%, 98%, or 99% sequence identity) to the humanized Y12XX-28, Y12XX-hz40, or Y12XX-hz42 sequence, respectively. Non-identical amino acid residues or amino acids that differ between the two sequences represent amino acid substitutions, additions, or deletions. Residues that differ between the two sequences may be identified using BLAST or similar techniques. (登録商標) These positions appear as non-identical positions when the two sequences are aligned by an appropriate amino acid sequence alignment algorithm, such as GABA (registered trademark of the US National Library of Medicine).
[0063] Exemplary CD40 antibodies of the invention include an isolated antibody that specifically binds to human CD40, or an antigen-binding portion thereof, wherein the antibody comprises a first polypeptide portion comprising a heavy chain variable region and a second polypeptide portion comprising a light chain variable region, wherein: The heavy chain variable region comprises one of: (i) a CDR1 comprising SYWMH (SEQ ID NO:1), a CDR2 comprising QINPTTGRSQYNEKFKT (SEQ ID NO:2), and a CDR3 comprising WGLQPFAY (SEQ ID NO:3); and (ii) a CDR1 comprising SYWMH (SEQ ID NO:1), a CDR2 comprising QINPSQGRSQYNEKFKT (SEQ ID NO:12), and a CDR3 comprising WGLQPFAY (SEQ ID NO:3); and The light chain variable region comprises CDR1 comprising KASQDVSTAVA (SEQ ID NO:7), CDR2 comprising SASYRYT (SEQ ID NO:8), and CDR3 comprising QQHYSTPWT (SEQ ID NO:9).
[0064] The isolated antibody or antigen-binding portion thereof may antagonize one or more activities of CD40. The isolated antibody or antigen-binding portion thereof may be a chimeric antibody. Exemplary variable heavy and variable light chains for chimeric antibodies are shown in Table 8 of the Examples. The isolated antibody or antigen-binding portion thereof may be a humanized antibody. Exemplary humanized variable heavy and variable light chains are shown in Table 10 of the Examples. The isolated antibody or antigen-binding portion thereof may comprise a human heavy chain constant region and a human light chain constant region.
[0065] Fc Domains and Constant Regions The carboxyl-terminal "half" of the heavy chain is defined as the constant region (Fc) and is primarily responsible for effector function. As used herein, the term "Fc domain" refers to a constant region antibody sequence comprising the CH2 and CH3 constant domains as defined in Kabat, et al., Sequences of Immunological Interest, 5th ed., US Dept. Health & Human Services, Washington, DC (1991). The Fc region may be derived from human IgG. For example, the Fc region may be derived from a human IgG1 or human IgG4 Fc region. The heavy chain variable domain may be fused to the Fc domain. The carboxyl terminus of the variable domain may be linked or fused to the amino terminus of the Fc CH2 domain. Alternatively, the carboxyl terminus of the variable domain may be linked or fused to the amino terminus of a linker amino sequence that is itself fused to the amino terminus of the Fc domain. Alternatively, the carboxyl terminus of the variable domain may be linked or fused to the amino terminus of a CH1 domain that is itself fused to the amino terminus of the Fc CH2 domain. Optionally, the protein may include all or part of a hinge region following the CH1 domain. Optionally, an amino acid linker sequence is present between the variable domain and the Fc domain. The carboxyl terminus of the light chain variable domain may be linked or fused to the amino terminus of the CL domain.
[0066] An exemplary sequence for heavy chain CH1 is amino acids 118-215 of SEQ ID NO:5 (ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRV; SEQ ID NO:18). An exemplary sequence for the light chain CL is amino acids 108-214 of SEQ ID NO:11 (RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC; SEQ ID NO:19).
[0067] The antibody may be a fusion antibody comprising a first variable domain which specifically binds human CD40, and a second domain comprising an Fc domain.
[0068] Exemplary Fc domains used in the fusion protein may include human IgG domains. Exemplary human IgG Fc domains include IgG4 Fc domains and IgG1 Fc domains. Human IgG heavy chain genes encode a lysine at the C-terminus, which is often lost from endogenous antibodies as a result of cleavage during circulation. When expressed in cultured mammalian cells, antibodies with IgG heavy chains that include a C-terminal lysine may also have variable levels of C-terminal lysine present (Cai et al., 2011, Biotechnol Bioeng. 108(2): 404-12). Thus, the C-terminal lysine of any of the IgG heavy chain Fc domains disclosed herein may be excluded.
[0069] The isolated antibody or antigen binding portion described herein may comprise an Fc domain comprising the amino acid sequence: EPKSCDKTHTCPPCPAPELLGG(P / K)SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY(N / A)STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR(D / E)E(L / M)TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG(K / absent) (Fc consensus; SEQ ID NO: 21). The notation in brackets indicates the possible amino acid identifier at that position. For example, position 238 of kabat is written as (P / K) and can be either proline (P) or lysine (K). As additional examples, non-restrictive consensus sequences are shown in SEQ ID NOs:118-120.
[0070] The isolated antibody or antigen-binding portion thereof described herein may comprise a human IgG1 Fc domain comprising a mutation at Fc gamma receptor (FcγR) binding residue kabat position 238, where proline 238 (P238) is mutated to one of the residues selected from the group consisting of lysine (K), serine (S), alanine (A), arginine (R), and tryptophan (W), and where the antibody or antigen-binding portion thereof has reduced binding to FcγR. The isolated antibody or antigen-binding portion thereof described herein may comprise a mutation of P238 to lysine in the human IgG1 Fc domain.
[0071] The isolated antibody or antigen-binding portion thereof comprises an Fc domain comprising an amino acid sequence selected from SEQ ID NO:22-29.
[0072] Exemplary sequences containing the IgG1 Fc domain include: SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:30, and SEQ ID NO:31.
[0073] The isolated antibody or antigen-binding portion thereof described herein can comprise a human IgG1 Fc domain comprising a Kabat alanine substitution at position 297. For example, the isolated antibody or antigen-binding portion thereof comprises an Fc domain comprising an amino acid sequence selected from SEQ ID NOs: 32-39.
[0074] The isolated antibody or antigen-binding portion thereof described herein comprises: (1) a variable heavy chain (VH) selected from Table 8 or Table 10 in the Examples; H ), or its CDRs, and / or (2) a variable light chain (V L ), or its CDRs.
[0075] The isolated antibody or antigen-binding portion thereof disclosed herein may comprise a heavy chain amino acid sequence selected from Vh-hz12 (SEQ ID NO: 13) and Vh-hz14 (SEQ ID NO: 4).
[0076] The isolated antibody, or antigen-binding portion thereof, disclosed herein may comprise a light chain amino acid sequence selected from Vk-hz2 (SEQ ID NO: 10) and Vk-hz3 (SEQ ID NO: 16).
[0077] The isolated antibody or antigen-binding portion thereof disclosed herein may be an antibody selected from the group consisting of: a) Y12XX-hz28-P238K having a heavy chain of SEQ ID NO: 5 or 6 and a light chain of SEQ ID NO: 11; b) Y12XX-hz40-P238K having a heavy chain of SEQ ID NO: 14 or 15 and a light chain of SEQ ID NO: 17; and c) Y12XX-hz42-P238K having a heavy chain of SEQ ID NO: 5 or 6 and a light chain of SEQ ID NO: 17.
[0078] An isolated antibody or antigen-binding portion thereof disclosed herein, wherein the antigen-binding portion is selected from the group consisting of Fv, Fab, F(ab')2, Fab', dsFv, scFv, sc(Fv)2, diabody, and scFv-Fc.
[0079] The antibodies or antigen-binding portions thereof disclosed herein may be an immunoconjugate in which the antibody or antigen-binding portion thereof is linked to a therapeutic agent.
[0080] The antibodies or antigen-binding portions thereof disclosed herein may be bispecific antibodies, in which the antibody or antigen-binding portion thereof is linked to a second functional moiety that has a different binding specificity than the antibody or antigen-binding portion thereof.
[0081] The antibodies or antigen-binding portions thereof disclosed herein may further comprise additional moieties.
[0082] The variable region of the antibody may be optionally linked to the Fc domain by an "amino acid linker", or "linker". For example, the C-terminus of the variable heavy domain may be fused to the N-terminus of the amino acid linker, and the Fc domain may be fused to the C-terminus of the linker. The amino acid linker may be of any length and any combination of amino acids, although the linker length may be relatively short (e.g., 5 or fewer amino acids) to reduce interactions between the linked domains. The amino acid composition of the linker may also be adjusted to reduce the number of amino acids with bulky side chains or amino acids prone to secondary structure. Suitable amino acid linkers include, but are not limited to, those up to 3, 4, 5, 6, 7, 10, 15, 20, or 25 amino acids in length. Exemplary amino acid linker sequences include GGGGS (SEQ ID NO: 40) and linkers containing 2, 3, 4, or 5 copies of GGGGS (SEQ ID NOs: 41-44, respectively). Table 7 shows the sequences of linkers suitable for use in the present disclosure. [Table 7]
[0083] Preparation of antibodies Antibodies may be produced in a suitable mammalian host cell line, such as CHO, 293, COS, NSO, etc., using conventional techniques, and then purified using one or a combination of methods including Protein A affinity chromatography, ion exchange, reverse phase techniques, etc.
[0084] As is well known to those skilled in the art, multiple codons can code for the same amino acid. Thus, nucleic acids encoding proteins include nucleic acids with degeneracy of codons. The polypeptide sequences disclosed herein can be encoded by various kinds of nucleic acids. The genetic code is universal and well known. Nucleic acids encoding any polypeptide sequence disclosed herein can be easily conceived and optimized for production based on prior knowledge in the art. Although the number of possible nucleic acids encoding the polypeptide is large, with the aid of a standard table of genetic code and a computer, a person skilled in the art can easily generate all possible combinations of nucleic acid sequences encoding the polypeptide.
[0085] An exemplary nucleic acid sequence encoding the Y12XX heavy chain variable domain of Y12XX-hz28, including the constant region CH1 and the Fc domain IgG1-P238K, is as follows:
[0086] A representative nucleic acid sequence encoding the Y12XX light chain variable domain of Y12XX-hz28, including the constant region CL, is shown below: (SEQ ID NO: 50). In this sequence, nucleic acids 1 to 51 encode a signal peptide (any), nucleic acids 52 to 372 encode a light chain variable region, of which nucleic acids 121 to 153 encode CDR1, nucleic acids 199 to 219 encode CDR2, and nucleic acids 316 to 342 encode CDR3. Nucleic acids 373 to 693 encode CL. Nucleic acids 694 to 696 are stop codons.
[0087] The coding sequence for the heavy and / or light chain may optionally encode a signal peptide at the 5' end of the coding sequence, such as, for example, MRAWIFFLLCLAGRALA (SEQ ID NO:51). As noted above, an exemplary nucleic acid coding sequence for this signal peptide is ATGAGGGCTTGGATCTTCTTTCTGCTCTGCCTGGCCGGGAGAGCGCTCGCA (SEQ ID NO:52).
[0088] Thus, also contemplated is a nucleic acid encoding an antibody disclosed herein. Such a nucleic acid may be inserted into a vector, e.g., an appropriate expression vector, such as pHEN-1 (Hoogenboom et al. (1991) Nucleic Acids Res. 19: 4133-4137). Further provided is an isolated host cell comprising the vector and / or the nucleic acid.
[0089] The antibodies of the disclosure may be produced and purified using only conventional techniques in a suitable mammalian host cell line, such as CHO (Chinese hamster ovary cells), 293 (human embryonic kidney 293 cells), COS cells, NSO cells, and the like, and then purified using one or a combination of methods including Protein A affinity chromatography, ion exchange, reverse phase techniques, and the like.
[0090] Pharmaceutical Compositions and Methods of Treatment Pharmaceutical compositions include a therapeutically effective amount of one or more antibodies and any pharma- ceutical acceptable carrier. Pharmaceutically acceptable carriers include, for example, water, saline, phosphate buffered saline, dextrose, glycerol, ethanol, and the like, and combinations thereof. Pharmaceutically acceptable carriers may further include minor amounts of auxiliary substances, such as wetting agents, emulsifying agents, preservatives, or buffers that enhance the preservation and effectiveness of the fusion protein. The compositions may be formulated to provide quick, sustained, or delayed release of the active ingredient after administration. Suitable pharmaceutical compositions and processes for their preparation are known to those skilled in the art. See, for example, Remington, THE SCIENCE AND PRACTICE OF PHARMACY, A. Gennaro, et al., eds., 21st ed., Mack Publishing Co. (2005).
[0091] The pharmaceutical composition may be administered alone or in combination therapy (i.e., simultaneously or sequentially) with immunosuppressants / immunomodulators and / or anti-inflammatory agents. One exemplary class of agents is cytotoxic T-lymphocyte-associated protein 4 (CTLA4) mutant molecules. One example of a CTLA4 mutant molecule is L104EA29Y-Ig (belatacept), a modified CTLA4-Ig. Different immune diseases may require the use of specific adjuvant compounds effective in treating immune diseases, which are determined on a patient-by-patient basis. For example, the pharmaceutical composition may be administered in combination with one or more suitable adjuvants, such as cytokines (e.g., IL-10 and IL-13) or other immune stimulants, such as chemokines, tumor-associated antigens, and peptides. Suitable adjuvants are known to those skilled in the art.
[0092] A method of treating an immune disease in a patient in need of such treatment may include administering to the patient a therapeutically effective amount of an antibody, or an antigen-binding portion thereof, as described herein. Further provided is a method of treating or preventing an autoimmune disease or an inflammatory disease in a patient in need of such treatment, comprising administering to the patient a therapeutically effective amount of an antibody, or an antigen-binding portion thereof, as described herein. Also provided is the use of an antibody, or an antigen-binding portion thereof, or a pharma- ceutically acceptable salt thereof, of the present disclosure, for treating an immune disease in a patient in need of such treatment and / or for treating or preventing an autoimmune disease or an inflammatory disease in a patient in need of such treatment, which may include administering to the patient a therapeutically effective amount of the antibody, or an antigen-binding portion thereof. Antagonizing CD40-mediated T cell activation could inhibit unwanted T cell responses that occur, for example, during autoimmune reactions, transplant rejection, or allergic reactions. Inhibiting CD40-mediated T cell activation could alleviate the progression and / or severity of these diseases.
[0093] Also provided is the use of the antibodies and antigenic moieties thereof of the present disclosure, or pharma- ceutically acceptable salts thereof, in the preparation of a medicament for the treatment of an immune disease and / or for the treatment or prevention of an autoimmune or inflammatory disease in a patient in need of such treatment, which may be administered in combination with, for example, an immunosuppressant / immunomodulatory agent and / or an anti-inflammatory agent.
[0094] As used herein, "patient" refers to an animal, e.g., a mammal, including a human. The patient may be diagnosed with an immune disease. "Treatment" or "treating" or "treatment of" refers to a process associated with reducing the progression or severity of a symptom, disorder, condition, or disease. "Immune disease" refers to any disease associated with the development of an immune response in an individual, including a cellular and / or humoral immune response. Examples of immune diseases include, but are not limited to, inflammation, allergy, autoimmune disease, or graft-related disease. Thus, the patient may be diagnosed with an autoimmune disease or inflammatory disease. "Autoimmune disease" refers to any disease associated with the development of an autoimmune response in an individual, including a cellular and / or humoral immune response. Examples of autoimmune diseases include, but are not limited to, inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn's disease. Other autoimmune diseases include systemic lupus erythematosus, multiple sclerosis, rheumatoid arthritis, diabetes, psoriasis, scleroderma, and atherosclerosis. Graft-associated diseases include graft-versus-host disease (GVHD), acute transplant rejection, and chronic transplant rejection.
[0095] Diseases that may be treated by administration of an antibody of the present disclosure may be selected from the group consisting of Addison's disease, allergies, anaphylaxis, ankylosing spondylitis, asthma, atherosclerosis, atopic allergies, autoimmune diseases of the ear, autoimmune diseases of the eye, autoimmune hepatitis, autoimmune parotitis, bronchial asthma, coronary heart disease, Crohn's disease, diabetes, epididymitis, glomerulonephritis, Graves' disease, Guillain-Barre syndrome, Hashimoto's disease, hemolytic anemia, idiopathic thrombocytopenic purpura, inflammatory bowel disease, immune reactions to recombinant pharmaceuticals (e.g., factor VII in hemophilia patients), lupus nephritis, systemic lupus erythematosus, multiple sclerosis, myasthenia gravis, pemphigus, psoriasis, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome, spondyloarthropathy, thyroiditis, transplant rejection, vasculitis, and ulcerative colitis.
[0096] The pharmaceutical composition may be administered alone or as a combination therapy (i.e., simultaneously or sequentially) with immunosuppressants / immunomodulators and / or anti-inflammatory agents. Different immune diseases may require the use of specific adjuvant compounds effective in treating the immune disease, which are determined on a patient-by-patient basis. For example, the pharmaceutical composition may be administered in combination with one or more suitable adjuvants, such as cytokines (e.g., IL-10 and IL-13) or other immune stimulants, such as chemokines, tumor-associated antigens, and peptides. Suitable adjuvants are known to those skilled in the art.
[0097] Any suitable method or route may be used to administer the antibody, or antigen-binding portion thereof, or pharmaceutical composition. Routes of administration include, for example, intravenous, intraperitoneal, subcutaneous, and intramuscular administration. The therapeutically effective dosage of the antibody will depend on numerous factors, including, for example, the type and severity of the immune disorder being treated, the use of concomitant therapies, the route of administration of the antibody, or antigen-binding portion thereof, or pharmaceutical composition, and the patient's body weight. A non-limiting range for a therapeutically effective amount of a domain antibody is 0.1-20 milligrams per kilogram (mg / kg) of the patient's body weight, and in one embodiment, 1-10 mg / kg.
[0098] kit Kits useful for treating immune disorders in a human patient are provided. Kits useful for treating or preventing an autoimmune or inflammatory disorder in a human patient are also provided. The kits include (a) an amount of an antibody, or antigen-binding portion thereof, of the present disclosure, and (b) instructions for using the antibody, or antigen-binding portion thereof, in a method for treating an immune disorder, or instructions for using the antibody, or antigen-binding portion thereof, in a method for treating or preventing an autoimmune or inflammatory disorder in a patient.
[0099] The term "instructions" as used herein includes publications, recordings, drawings, or any other medium of expression that can be used to communicate the usefulness of the compositions and / or compounds of the invention in a kit. The instructions for the kit can be, for example, affixed to a container containing the compounds and / or compositions of the invention or shipped together with a container containing the compounds and / or compositions. Alternatively, the instructions can be shipped separately from the container with the intention that the recipient will use the instructions and the compounds together. Delivery of the instructions can be, for example, by physically delivering a publication or other medium of expression that communicates the usefulness of the kit, or alternatively, can be obtained by electronic transmission, for example, by computer-based email or download from a website. EXAMPLES
[0100] Example 1: Binding of mouse anti-human CD40 antibodies to human CD40 Murine anti-human CD40 antibodies were produced and tested for binding to human CD40 by surface plasmon resonance (SPR). The Vh and Vk sequences of each antibody are shown in Table 8. [Table 8-1] [Table 8-2] [Table 8-3] [Table 8-4] [Table 8-5]
[0101] CD40 kinetics and affinity data were assessed by SPR upon binding of human CD40 monomer to a mouse anti-human CD40 antibody captured on a Protein A sensor chip surface. The data are shown in Table 9. The data shown are at a single concentration of CD40 analyte (1 μM) and are therefore reported as apparent values (app). [Table 9]
[0102] Based on the SPR and sequence data, three antibodies, ADX_Y1258.ZZ0-1, ADX_Y1262.ZZ0-1, and ADX_Y1268.ZZ0-1, were selected for humanization.
[0103] Example 2: Humanization and selection of Y12XX humanized variants The background / procedures for humanization are discussed in Section II "Engineered and Modified Antibodies" in WO2017004006, which is incorporated herein by reference in its entirety. Based on this analysis, nine humanized Vh sequences (Vh-hz1, Vh-hz2, Vh-hz3, Vh-hz4, Vh-hz5, Vh-hz6, Vh-hz9, Vh-hz10, and Vh-hz11) and three humanized Vκ sequences (Vk-hz1, Vk-hz2, and Vk-hz3), were selected for testing. Additionally, five humanized Vh sequences (Vh-hz7, Vh-hz8, Vh-hz12, Vh-hz13, Vh-hz14) were designed to contain mutations intended to reduce the liability risk of the engineered chemicals. Such mutations include D100Q (Y1262_IGHV1.6908-D100Q) and P101A mutations (Y1262_IGHV1.6908-P101A) to reduce potential hydrolysis risk in Y1262_IGHV1.6908. Such mutations also include N55Q (Y1268_IGHV1.6908-N55Q), G56A (Y1268_IGHV1.6908-G56A), and S54T-N55T double mutations (Y1268_IGHV1.6908-S54T-N55T) to reduce potential deamidation risk in Y1268_IGHV1.6908. The S54T-N55T double mutation was designed based on the corresponding amino acid residues found at these positions in ADX_Y1262.ZZ0-1-Vh. See Table 10.
[0104] The sequences of these variants are shown in Table 10. [Table 10-1] [Table 10-2] [Table 10-3]
[0105] Table 10 shows the BIAcore (商標) The sequences of the heavy and variable light domains used in the construction of humanized antibodies and chimeric antibody controls for CD40 binding analysis using surface plasmon resonance (SPR) and Octet BLI titer analysis (described below) are provided.
[0106] The Vh sequences were formatted with the IgG1-p238K isotype (CH1-IgG1-P238K; SEQ ID NO: 25). The Vκ sequences were formatted with the consensus CL sequence (amino acids 108-214 of SEQ ID NO: 11) as the full-length light chain. In Table 11, "Y1258" and "Y1262" refer to chimeric molecules containing mouse variable regions and human constant regions. Various different combinations of humanized HC and LC constructs and chimeric Y1258 and Y1262 molecules were expressed as 3 milliliters (ml) of supernatant for titer and CD40 binding analysis. This family of molecules was collectively identified with the prefix "Y12XX" and the suffix "hz#" to uniquely identify the different heavy / light chain pairs.
[0107] Titer analysis was performed on an OctetRED instrument (Fortebio) using biolayer interferometry (BLI) by capturing antibodies from the supernatants with a Protein A sensor chip and measuring the capture response and comparing it to a standard curve obtained with a control antibody sample. SPR data was obtained using BIAcore by capturing antibodies on a Protein A surface and testing binding of 500 nM and 50 nM injected human CD40 analyte. (商標) Acquired using a T200 instrument (GE Healthcare). Kinetic data for two concentrations of hCD40 monomer were fitted with a 1:1 Langmuir model to calculate estimates of the kinetics and affinity values of these interactions and to allow comparisons between different molecules.
[0108] Octet titer and BIAcore (商標)SPR CD40 binding data is provided in Table 11. In addition to testing supernatant ("sup") samples, human wild-type IgG1f isotype [ka] Purified chimeric Y1258, Y1262 and Y1268 antibodies containing were tested in SPR as controls; these are designated "Y1258-hIgG1f", "Y1632-hIgG1f", and "Y1268-hIgG1f" in Table 11, and the Vh and Vk chains are designated as "Chim-P". [Table 11-1] [Table 11-2]
[0109] For a given heavy chain construct, potency was generally highest when paired with a light chain containing Vk-hz3 (SEQ ID NO: 18), lower for heavy chains paired with light chains containing Vk-hz2 (SEQ ID NO: 10), and lowest for heavy chains paired with light chains containing Vk-hz1 (SEQ ID NO: 116).
[0110] The SPR analysis data showed that the antibodies bound to CD40 with varying affinities, with KD values ranging from greater than 1E-07 to less than 1E-09. For some antibodies, the affinity was too strong to be reliably and accurately determined in this assay because the dissociation rates were too slow to be measured. These values, shown in italics in the table, are beyond the precise quantitation limit of the assay.
[0111] Antibodies were selected based on sequence, potency, and SPR binding data for larger scale expression, purification, and further evaluation. SPR analysis with purified antibodies was performed by capturing the antibodies on Protein A and binding to a dilution series of 500-3.9 nM (2:1) human CD40 monomer in PBS-T pH 7.1 buffer at either 25° C. or 37° C., and potency data was fit to a 1:1 Langmuir model. This data is provided in Table 12. [Table 12]
[0112] These data show that the selected Y12XX antibodies bind with high affinity, with K values in the range of KD=1E-9 M at 25° C. Binding is compared to that of another anti-CD40 antibody, antibody BI-mAb-B (U.S. Pat. No. 9,090,696, heavy chain SEQ ID NO: 32 and light chain SEQ ID NO: 31; referred to herein as "Antibody B" and "BI-LALA"). As shown by the data in Table 12, Antibody B binds CD40 with a much lower affinity than the humanized Y12XX molecule.
[0113] All three humanized Y12XX antibodies were potent antagonists of B cell proliferation stimulated by the CD40-IZ trimer agonist. See Table 13. [Table 13]
[0114] Y12XX-hz28-P238K was also a potent antagonist of B cell proliferation stimulated with cellular CD40L from CD40L-expressing CHO cells. See Table 14. [Table 14] *Inhibition rate at the highest dose tested (1-3μg / ml)
[0115] Comparing the data for the humanized Y12XX antibodies with that for Antibody B, Antibody B demonstrated potent inhibition of B cell proliferation driven by soluble CD40L signals, but was significantly less effective at inhibiting B cell proliferation driven by cellular CD40L (CHO cell overexpressed CD40L). In contrast, the humanized Y12XX antibodies demonstrated only a less than 10-fold shift in potency in inhibiting cell surface CD40L stimulation, providing a more potent blockade of B cell responses to CD40L.
[0116] To reduce binding affinity to FcγR and reduce FcγR-mediated signaling, humanized Y12XX antibodies were formatted with the IgG1-P238K isotype (CH1-IgG1-P238K; SEQ ID NO: 25). FcγR binding of a representative humanized Y12XX antibody with this IgG-P238K isotype (Y12XX-hz28-IgG1-P238K) was compared to that of a control antibody formatted with wild-type IgG1 isotype (Control-IgG1) and antibody B with an IgG1 isotype containing the L234A-L235A mutations. These L234A-L235A mutations also induce reduced FcγR binding.
[0117] FcγR binding SPR studies were performed by capturing antibodies on a Protein A sensor chip surface and binding purified His-tagged human FcγR as the analyte. hCD64 binding consisted of a titration of 10 μM-1.5 nM hCD64 (2:1 dilution series), while data for the low affinity FcγRs hCD32a-H131, hCD32a-R131, hCD32b, hCD16a-V158, and hCD16a-F158 consisted of a titration of 10 μM-13.7 nM FcγR protein.
[0118] The control IgG1 antibody showed binding to all FcγRs tested. See Figure 1A. Compared to wild type, the Y12XX-hz28-IgG1-P238K antibody showed 125-fold weaker binding to hCD64 and no detectable binding to any of the low affinity FcγRs tested: hCD32a-H131, hCD32a-R131, hCD32b, hCD16a-V158, and hCD16a-F158. See Figure 1B. Antibody B also showed weaker binding to hCD64 than wild type IgG1, but also showed clear binding to hCD16a-V158 (KD=7 μM), as well as somewhat weaker binding to hCD32a-H131 and hCD32-R131. See Figure 1C. KD values are provided in Figure 1D.
[0119] The humanized version of the antibody Y12XX, which has a P238K mutation in the Fc region, was further tested for any agonistic activity. Monocyte-derived immature dendritic cells (iDCs) are highly sensitive to CD40 activation, and CD40 stimulation increases cytokine production (IL-6) and promotes the expression of cell surface markers of activation (CD86 and CD54). Thus, the most promising humanized Y12XX antibodies were tested to evaluate their iDC stimulatory capacity. The CD40 agonistic capacity of CD40 antibodies can be enhanced by clustering or cross-linking of the Fc portion of the molecule to FcγRs on the cell surface. The addition of CHO cells that highly overexpress the low affinity FcγR CD32a was used to evaluate the possibility of FcγR-mediated clustering / cross-linking. The ratio of CHO cells to iDCs in these experiments was 1:6, which may have exaggerated the level of clustering / cross-linking. BMS-986090 and 2141 were used as positive controls. BMS-986090 is an anti-CD40 antagonist domain antibody fused to IgG4Fc (see SEQ ID NO: 1287 in WO2012 / 145673). 2141 (mAb134-2141) is a partial CD40 agonist (see Robert Vonderheide et al., 2007, J. Clin. Oncol. 25(7): 876-883). L6-IgG4 is a fusion protein with no CD40 binding ability and was used as a negative control.
[0120] As shown by the data in Figure 2, addition of either the partial agonist 2141 or BMS-986090 only weakly activated iDCs in a subset of donors. However, addition of CD32a-expressing CHO cells to either 2141 or BMS-986090 strongly increased IL-6 production (Figure 2B) and promoted expression of CD86 and CD54 (Figures 2B and 2C, respectively) in almost all donors tested, consistent with FcγR-mediated clustering of CD40 through the Fc portion of these molecules. However, neither Y12XX-hz28-P238K nor Y12XX-hz40-P238K alone or CD32-dependent clustering demonstrated any signal of iDC activation beyond that observed in the negative control with iDC cells from 6 to 10 donors. Y12xx-hz42-P238K was tested in cells from four donors and showed a weak activation signal in only one of the four donors, including IL-6 production and enhanced expression of CD86 and CD54, but unlike the activation seen with 2141 or BMS-986090, it was not dependent on the addition of CD32a-expressing CHO cells.
[0121] Materials and Methods for Examples 1 and 2 FcγR binding SPR: FcγR binding was measured in vitro using purified FcγR and BIAcore (商標) This can be measured using methods such as surface plasmon resonance (SPR). One method is to test the binding of purified His-tagged FcγR proteins (FcγR-His) to antibodies captured on a sensor surface containing immobilized Protein A using standard ethyl(dimethylaminopropyl)carbodiimide (EDC) / N-hydroxysuccinimide (NHS) chemistry and ethanolamine blocking. These experiments were performed using the BIAcore (商標)The experiments were carried out at 25°C using a T200 (GE Healthcare, Marlborough, MA) instrument. For example, a sample of purified antibody at a concentration of 3 μg / ml was first captured on the immobilized Protein A surface at a flow rate of 10 μL / min with a contact time of 15 seconds. This was then followed by binding of purified FcγR-His protein at various concentrations, e.g., 10 μM-1.5 nM (2:1 dilution series) or 10 μM-13.7 nM (2:1 dilution series), at a flow rate of 30 μL / min with association and dissociation times of 120 seconds. The entire run was carried out in 10 mM NaPO 4、 The running buffer consisted of 130 mM NaCl, 0.05% p20 (PBS-T) pH 7.1. The FcγR proteins tested in these studies included the "high affinity" FcγR CD64 (hFcγRI), and the "low affinity" FcγRs CD32a-H131 (FcγRIIa-H131), CD32a-R131 (FcγRIIa-R131), CD32b (FcγRIIb), CD16a-V158 (FcγRIIIa-V158), and CD16a-F158 (FcγRIIIa-F158), which were expressed and purified in-house. Association rate constants (Ka), dissociation rate constants (Kd), and dissociation constants (K D ) values, BIAcore (商標) The SPR data were fitted with either a 1:1 Langmuir model or a 1:1 steady-state model using the T200 evaluation software.
[0122] To compare the binding responses of different FcγRs, the SPR data can be analyzed by calculating the maximum binding response as a percentage of the theoretical maximum binding response (%Rmax) using the following equation:
number
[0123] CD40 binding kinetics and affinity: The monovalent CD40 binding affinity of antibody molecules was determined by surface plasmon resonance (SPR) at 25°C or 37°C using BiAcore (商標) SPR data was measured on a T200 instrument (GE Healthcare Life Sciences) by capturing the antibody on an immobilized Protein A sensor chip surface and binding human CD40 monomeric protein (produced in-house) in PBS-T, pH 7.1 at a flow rate of 30 μL / min using, for example, an association time of 180 s and a dissociation time of 180 s or 360 s. SPR data was analyzed using a BIAcore™ protocol to obtain association rate constant (Ka), dissociation rate constant (Kd), and dissociation constant (KD) values. (商標) A 1:1 Langmuir model was fitted using the T200 evaluation software.
[0124] Titer analysis: Titer analysis was performed at 25°C, Octet (登録商標) This was performed using BioLayer Interferometry (BLI) on a RED instrument (ForteBio, Freemont, CA). Antibodies were captured from the supernatant using a Protein A sensor chip with a binding time of 120 seconds, and the binding response was measured and compared to a standard curve obtained using control antibody samples to determine the antibody concentration in the supernatant.
[0125] Primary cell isolation and culture: Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized human blood by Ficoll density gradient separation. Monocytes were cultured using the Manual EasySep (商標)Monocytes were isolated from PMBCs according to the protocol (STEMCELL, vancouver, Canada). One million isolated monocytes were seeded in 6 ml of complete medium (RPMI-1640, 10% heat-inactivated fetal bovine serum, 100 units / ml penicillin-streptomycin) containing IL-4 (100 ng / ml) and GM-CSF (100 ng / ml) per well of a 6-well plate and incubated at 37°C / 5% CO2 for 6 days, changing the medium every other day and replacing it with fresh medium containing the same concentrations of cytokines. iDCs (immature dendritic cells) were harvested on day 6, washed extensively, and resuspended in complete medium.
[0126] Anti-CD40 antibody treatment of iDCs with or without FcγR clustering / cross-linking: Titrations of different biological agents were performed in complete medium and added in duplicate to 96-well plates. For cross-linking, antibodies were added to cells for 30 min, after which CD32a-expressing CHO cells were added at a ratio of 1:6. Cells were incubated for approximately 18-20 h at 37°C / 5% CO2, 150 μL of supernatant collected from each well was diluted at a ratio of 1:5, and protein concentrations of IL-6, TNFα, and IL-12 were assessed using commercial ELISA kits (R&D Systems, Minneapolis, MN) according to the manufacturer's instructions. Cells remaining in the plate from which the supernatant was collected were combined from duplicate treatment samples into one sample and transferred to a new round-bottom (RB) 96-well plate and placed at 4°C. Cells were washed with CA++- and Mg++-free D-PBS and stained with the LIVE / DEAD Fixable Near-Infrared Dead Cell Stain Kit (Invitrogen, Carlsbad, CA) for 30 min on ice to measure cell viability. Cells were washed and resuspended in CA++- and Mg++-free D-PBS, 2% FBS, 0.1% NaH3 (staining buffer) and stained with 5 μL / well of Human TruStain FcX in staining buffer. (商標) (Fc receptor blocking solution, Biolegend, San Diego, Calif.).
[0127] DCs were immunostained with the following and incubated for 45 min at 4°C: αCD3, αCD19, αCD14 (Lin ー ); αCD11c labeled with BUV395 (BD Biosciences, San Diego, CA); αCD86 labeled with APC (Biolegend, San Diego, CA); αCD83 labeled with PE (eBioscience, San Diego, CA); αCD54 labeled with FITC (Biolegend, San Diego, CA). Cells were washed twice with staining buffer and fixed by adding 100 μL of BD Cytofix fixation buffer (BD Bioscience, San Diego, CA) (15 min at room temperature, protected from light). Expression of CD86, ICAM-1, and CD83 on DCs was assessed using an LSRII-fortessa flow cytometer (BD Biosciences, San Diego, CA) and FlowJo analysis software (Treestar, Ashland, OR).
[0128] Inhibition of CD40L-induced human B cell proliferation: Human tonsillar B cells were obtained from pediatric patients during routine tonsillectomy, the tissue was finely minced, gently ground, the cells were passed through a screen, and then incubated with human lympholyte. (登録商標) Mononuclear cells were isolated by isolating mononuclear cells by density gradient separation using -H separation medium (Cedarlane Labs, Burlington, ON). Mononuclear cells were collected from the interface, washed, and rosetted with sheep red blood cells (SRBC, Colorado Serum Company; Denver, CO) for 1 hour at 4°C, followed by density gradient separation to remove T cells. Cells were washed again and resuspended in RPMI with 10% FBS (complete medium). Antibody titrations were added in complete medium in triplicate to 96-well round-bottom (RB) plates. 1X10 5Human tonsillar B cells were added and stimulated with either soluble IZ-hCD40L (2 μg / mL) or Chinese hamster ovary cells irradiated with 10,000 rad and stably transfected with human CD40L (CHO-hCD40L), with 2X10 3 Plates were incubated at 37°C and 5% CO2 for 72 hours and then treated with 0.5 μCi of IgG1 per well. 3 B cells were labeled with [H]-thymidine for the final 6 hours, harvested, and counted by liquid scintillation. B cell proliferation was quantified based on thymidine incorporation.
[0129] Example 3: In Vitro Fc Receptor Assay. The Fc region of an antibody can exhibit effector functions such as complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) by binding to Fc gamma receptors (FcγR) on the surface of immune cells or binding to complement factors. Antibody-dependent cellular phagocytosis is another potential Fc effector function. To further evaluate the performance of humanized Y12XX antibodies, the antibodies were assayed for complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP), and antibody-dependent cellular cytotoxicity (ADCC). Table 15 shows the antibodies assayed in this example. [Table 15]
[0130] CDC assays were performed as follows: "CDC assay medium" refers to Roswell Park Memorial Institute medium (RPMI)-1640 (Hyclone) supplemented with L-glutamine and without phenol red (Hyclone), with 0.1% BSA (Sigma), and 1% penicillin-streptomycin (Life Technologies). 50 μL of target cells (5x10 5Cells / mL in CDC assay medium were added to a 96-well assay plate. Target cells were Raji cells (obtained from ATCC) that endogenously express CD40. A dilution series (133 to 0.002 nM) was prepared for each antibody being tested, and 25 μL of each antibody concentration was added to each well. 25 μL of human complement (obtained from Quidel, diluted 1:3 in CDC assay medium) was added to each well. The assay plate was incubated at 37°C in a humidified incubator for 4 hours. After incubation, 100 μL of CellTiter-Glo (登録商標) (Promega, Madison, WI) was added to each well, and PerkinElmer EnVision (登録商標) Fluorescence data was acquired using a plate reader (PerkinElmer, Waltham, MA). Viability was calculated relative to isotype control (100% viability). Resulting values were plotted against antibody concentration. Cell viability was plotted against each antibody using Prism v5.01 software from GraphPad Inc.
[0131] The CDC assay was performed twice. Freshly thawed human complement serum was used in the second assay. The results are shown in Figure 3. Figure 3A shows the first repeat of the assay, and Figure 3B shows the second repeat of the assay. CD20 hIgG1 is a positive control and shows cytotoxicity. There was no detectable CDC activity for the anti-CD40 antibodies assayed, and in particular, none of the humanized Y12XX antibodies assayed induced complement-dependent cytotoxicity.
[0132] The ADCP assay was performed as follows. "ADCP assay medium" refers to L-glutamine, phenol red-free (hyClone) RPMI-1640 medium supplemented with 10% ultra-low concentration IgG FCS (Giblo). Effector cells were primary human CD14+ monocytic cells purified from fresh PBMCs from two different healthy human donors. Target cells were again Raji cells. Raji cells were labeled with 2.0 μM PKH26 (red fluorescent dye; Sigma) and diluted at a concentration of 4 × 10 in ADCP assay medium. 6 The antibody concentrations were adjusted to 100 μL / ml. Labeled target cells were pre-coated with antibody by adding labeled target cells (50 μL / well) to a V-bottom 96-well plate containing 50 μL / well of test or control antibody and incubated on ice for 30 min. Target cells were washed and effector cells (CD14+ monocytic cells) were added (100 μL / well) to a final effector to target cell ratio (E:T) of 1:4 and final antibody concentrations ranging from 30 nM to 0.1 nM. Plates were then placed in a humidified 37°C incubator for 1 h. Cells were stained with APC-anti-CD89 (BioLegend) for 30 min on ice and analyzed using a flow cytometer (BD Canto (商標) The cells were analyzed using a 3D ELISA Kit (BD Bioscience, San Jose, CA). Cells were sorted into CD89+ cells and then stained for phagocytic effector cells (CD89+, PKH26+). The percentage of phagocytosis was calculated as the number of CD89+, PKH26+ cells among total CD89+ cells. Background values calculated from isotype controls were subtracted to obtain the final percentage of phagocytosis. Data were analyzed using FrowJo software and Prism v5.01 software from Graphpad Inc.
[0133] Exemplary data using CD14+ monocytic cells from two different donors is shown in Figure 4. CD20 hIgG1 is a positive control and induces phagocytosis of Raji cells as expected. BMS-986090 also induces phagocytosis. In contrast, none of the other antibodies tested, including the humanized Y12XX anti-CD40 antibodies of the present disclosure, induce detectable phagocytosis in this assay.
[0134] The ADCC assay was performed as follows. "ADCC assay medium" refers to L-glutamine, phenol red-free RPMI-1640 medium (hyClone) supplemented with 10% ultra-low IgG FBS (Giblo), and 1 mM sodium pyruvate (Life Technologies). Primary human NK (natural kill) cells were purified from fresh PBMCs from two different in-house donors and used as effector cells. PBMCs were purified by density gradient centrifugation from heparinized whole blood samples and washed with PBS supplemented with 2% FBS (HyClone). NK cells were isolated from PBMCs by negative selection using a magnetic bead-based isolation kit (Miltenyi Biotec). To activate NK cells, purified NK cells were cultured at 1x10 in MyeloCult H5100 medium (StemCell Technologies) supplemented with 1 μM hydrocortisone (StemCell Technologies) and 500 IU / ml recombinant human IL-2 (Peprotech). 6 The activated NK effector cells were resuspended at 5 × 10 cells / ml and incubated overnight at 37°C. The following day, the activated NK effector cells were washed twice with ADCC assay medium and their concentration was adjusted to 5 × 10 5The reconstituted calcein AM was added per ml of suspended Raji cells; the cells were vortexed and placed in a humidified incubator for 30 min. After the incubation period, the labeled target cells were washed three times with ADCC assay medium and diluted to a concentration of 10 in ADCC medium. 5 The labeled target cells (50 μL / well) were added to a V-bottom 96-well plate containing 50 μL / well of test or control antibody. Activated NK cells were then added (100 μL / well) to a final effector to target cell ratio (E:T) of 10:1 and final antibody concentrations ranging from 0.0002 to 1 μg / ml. Plates were then placed in a humidified 37°C incubator for 2 hours. Supernatants (50 μL / well) were transferred to an optical 96-well black plate and calcein emission was monitored using an EnVision RT-PCR system with 485 excitation and 535 nm emission filters. (登録商標) Fluorescence intensity was measured using a plate reader (PerkinElmer, Waltham, Mass.).
[0135] In this assay, target cells incubated with effector cells in the absence of antibody serve as a background control for antibody-independent lysis (spontaneous lysis), while target cells lysed with 20 μL / well of 10% Tween-20 lysis buffer represent maximum release.
[0136] The percentage of antibody-dependent cytolysis was calculated based on the mean fluorescence intensity (MFI) according to the following formula:
number
[0137] Exemplary data using NK cells from two different donors are shown in Figure 5. Target cells were killed by a positive control anti-CD20 antibody, whereas ADCC was low to negative for all anti-CD40 antibodies, indicating that these antibodies do not induce antibody-dependent cytotoxicity of Raji cells, proving that these antibodies are CD40 antagonists.
[0138] In summary, in this example, the humanized Y12XX anti-CD40 antibodies of the present disclosure, specifically Y12XX-hz28-P238K, Y12XX-hz40-P238K, and Y12XX-hz42-P238K, were tested for their potential to mediate ADCC (antibody-dependent cellular cytotoxicity), ADCP (antibody-dependent cellular phagocytosis), or CDC (complement-dependent cytotoxicity) using endogenous CD40-expressing Raji cells as targets. Anti-CD20 antibodies were used as a positive control. For ADCC, two experiments were performed using effector cells from different donors, using NK cells as effector cells. In both cases, none of Y12XX-hz28-P238K, Y12XX-hz40-P238K, and Y12XX-hz42-P238K induced lysis of Raji cells. Under the influence of human IgG1 isotype control, none of Y12XX-hz28-P238K, Y12XX-hz40-P238K, and Y12XX-hz42-P238K induced CDC of Raji cells. For ADCP, using CD14+ monocytic cells as effector cells, none of Y12XX-hz28-P238K, Y12XX-hz40-P238K, and Y12XX-hz42-P238K promoted cell phagocytosis in this system. On the other hand, BMS-986090 showed cell phagocytosis.
[0139] Example 4: NF-κB / AP-1 signaling assay The purpose of this example is to determine whether Ramos-Blue is a result of stimulation with anti-CD40 antibodies. (商標) The objective of this study was to evaluate the activity of NF-κB / AP-1-induced SEAP (secreted embryonic alkaline phosphatase) in IL-1 cells (InvivoGen).
[0140] Ramos-Blue (商標) The cells are a human B lymphocyte reporter cell line expressing the NF-κB / AP-1 inducible secreted embryonic alkaline phosphatase (SEAP) reporter gene. Ramos-Blue (商標) The cell lines were used for NF-κB / AP-1 signaling and Toll-like receptor (TLR) signaling pathways, and Ramos-Blue (商標) The cells endogenously express CD40 and are CD40 and TLR sensitive. Ramos-Blue (商標) When the cell lines are stimulated, they produce SEAP in the cell culture supernatant. SEAP is expressed by QUANTI-Blue (商標) Detection can be performed using detection medium (InvivoGen, San Diego, Calif.). The level of SEAP can be observed visually or using a spectrophotometer at 620 nm. Ramos-Blue (商標) The cells do not express CD32 (FcγRII).
[0141] The test substances (antibodies and other polypeptides) assayed in this example are listed in Table 16. All test substances were prepared in-house at BMS. [Table 16]
[0142] Ramos-Blue (商標) The cells were purchased from InvivoGen. For this assay, the transformed cell line, designated herein as Ramos-Blue cell #4, was used as a Ramos-Blue (商標)The cells were transfected with human CD32 (FcγRII). (商標) Cells were cultured in Ramos cell culture medium (Iscove's modified Dulbecco's medium (IMDM) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, penicillin and streptomycin (100 U / ml, -100 μg / ml), normocin at 100 μg / ml, and zeocin (100 μg / ml) for drug selection). Cells were cultured at 37°C and 5% CO2. Both types of cells were passaged every 3 days and cultured at 0.5 × 10 6 The cells were maintained at a cell density of 1000 cells / ml. The cells were used up to cell passage number #21 (P21). After P21, the cells were discarded.
[0143] The assay was performed as follows: (商標) "Medium" refers to serum-free medium (Thermo Fisher Scientific) supplemented with L-glutamine, 50 μg / ml streptomycin sulfate, and 10 μg / ml gentamicin sulfate. Ramos-Blue (商標) To evaluate CD40 agonist activity using CD40 antagonist antibody against NF-κB / AP-1 activity in cell #4, cells were incubated in AIM V medium without the antibiotics normocin / zeocin. (商標) The cells were washed twice with medium. The cells were then centrifuged at 2000 rpm for 10 min at room temperature. The medium was carefully aspirated off without disturbing the cell pellet. 1 ml of AIM V was added. (商標) Add 1 mL of AIM V to the cell pellet, resuspend the cell pellet, and add an additional 9 mL of AIM V. (商標) After resuspension, 20 μL ViaStain was added. (商標) AOPI (acridine orange / propidium iodide) staining solution (Nexcelom Bioscience, LLC, Lawrence, MA) and 20 μL of Ramos-Blue (商標) A cell suspension was added and the cells were counted using a cell counter.
[0144] Ramos-Blue (商標) The cells are AIM V (商標)4 × 10 in serum-free medium 6 The cells were then adjusted to 400,000 cells / ml per well in a flat-bottom tissue culture plate, with 100 μL of Ramos-Blue. (商標) Cells were added, and 100 μL of BMS-986325, BMS-986090, mAb134-2141 (CD40-2142), or control was added to each corresponding well. CD40L-IZ was used as a positive control. AIM V (商標) Ramos-Blue inside (商標) cells (0.4×10 6 Cells / well) were included as a negative control in the assay. The final volume was 200 μL / well.
[0145] The plates were incubated for 20 hours in a 37° C., 5% CO2 incubator. After 20 hours of cell culture, the plates were centrifuged at 2000 rpm for 10 minutes.
[0146] 40 μL of cell culture supernatant from stimulated Ramos cells was added to the wells of a flat-bottom plate, and 160 μL of QUANTI-Blue (商標) The solution was added to each well, the final volume was 200 μL / well.
[0147] The plates were incubated for 1-6 hours in a 37°C, 5% CO2 incubator. SEAP levels were measured using EnVision (登録商標) Measurements were taken every 60 min at 620 nm using an optical reader (OD: 620 nm).
[0148] Exemplary data are shown in Figure 6. In this example, CD32-deficient Ramos-Blue (商標) Ramos-Blue transformed cells or CD32 (商標) Anti-CD40 monoclonal antibodies were tested against Ramos-Blue#4 cells, and the Ramos-Blue cells stimulated with anti-CD40 antibodies were (商標) NF-κB / AP-1-induced SEAP activity in cells was assessed.
[0149] Addition of CD40-2142 induced a significant signal response in this assay (Figures 6A and 6B). These results suggest that CD40-2142 is a full agonist in this assay system. (商標) No response was observed with the addition of BMS-986090 using Ramos-Blue cells #4 (CD32-transfected Ramos-Blue) (Figure 6A), whereas no response was observed with the addition of BMS-986090 using Ramos-Blue cells #4 (CD32-transfected Ramos-Blue) (商標) In the assay using CD40L-IZ (Figure 6B), partial agonism was observed, suggesting that the agonistic response induced by the addition of BMS-986090 is mediated in an FcγR-dependent manner. As reflected in Figures 6C and 6D, the control polypeptide, CD40L-IZ trimer, induced responses in both assays.
[0150] On the other hand, the addition of BMS-986325 inhibited the activity of Ramos-Blue (商標) cells (CD32 - ) (Figure 6A) or Ramos#4 (CD32 + ) (Figure 6B) did not induce significant NF-κB / AP-1 responses. These data suggest that BMS-986325 does not agonize CD40 and does not associate with CD32 (FcγR). These data suggest that reducing association with low affinity FcγRs, such as CD32 (FcγRII), helps reduce the potential for unwanted agonist signaling and unwanted cytotoxicity.
[0151] Example 7: Summary of non-clinical pharmacokinetic evaluation of BMS-986325 The pharmacokinetics (PK) of BMS-986325 (Y12XX-hz28-P238K) in mice and cynomolgus monkeys was evaluated. Because BMS-986325 does not cross-react with mouse CD40 receptors, the PK evaluated in mice was intrinsic or nonspecific PK. Because BMS-986325 cross-reacts with monkey CD40 receptors, total PK (specific and nonspecific PK) was evaluated in monkeys. After intravenous (IV) administration of BMS-986325 (single 1- and 10-mg / kg doses) to mice, BMS-986325 exhibited a low total serum clearance (CLT) of 0.5 to 1.02 ml / d / kg, a limited steady-state volume of distribution (Vss) of 0.12 to 0.19 L / kg, and a long apparent elimination half-life (T-HALF) of 118 to 183 hours (~5 to 8 days).
[0152] A single subcutaneous (SC) dose of BMS-986325 was administered in monkeys at a dose such that specific clearance (target-mediated drug disposition, "TMDD") was not saturated. After a single SC dose, BMS-986325 was well absorbed with an absolute bioavailability of 70.4% (compared to exposure at the same IV dose). After IV administration of BMS-986325 to monkeys (single 10 mg / kg dose), BMS-986325 exhibited a CLT of 0.41 ml / d / kg, a limited Vss of 0.05 L / kg, and a T-HALF of 100 hours (approximately 4 days). The time to maximum plasma concentration, "Tmax," following single SC administration of BMS-986325 to monkeys (administered at doses of 1, 10, and 100 mg / kg) ranged from 24 to 54 hours. There was a more than dose-proportional increase in exposure (maximum concentration "Cmax" and area under the concentration-time curve extrapolated from time zero to infinity "AUC[INF]") and a dose-dependent increase in T-HALF (~31, ~119, and ~197 hours at 1, 10, and 100 mg / kg, respectively). These data suggest saturation of nonlinear PK and clearance mechanisms; this may be the result of target (CD40)-mediated clearance, reflecting TMDD. In this single-dose PK study, anti-drug antibody (ADA) formation was detected in ~50% of monkeys, but had no apparent effect on overall PK parameters.
[0153] Pharmacokinetic / pharmacodynamic modeling (TMDD model assuming quasi-steady state [TMDD-Qss]) was used to describe the nonlinear PK observed in monkeys and to establish the relationship between drug exposure in serum and CD40 receptor occupancy (RO), and subsequently to predict dosing in humans.
[0154] Although the present embodiment has been described in detail with reference to the examples as above, it is understood that various modifications can be made without departing from the spirit of these embodiments, and that such modifications can be readily known to those skilled in the art.
[0155] These and other aspects disclosed herein, including the exemplary specific methods of treatment, medicaments, and uses set forth herein, will be apparent from the teachings contained herein.
Claims
1. 1. A nucleic acid molecule encoding an isolated antibody or an antigen-binding portion thereof that specifically binds to human CD40, wherein the antibody comprises a first polypeptide portion comprising a heavy chain variable region and a second polypeptide portion comprising a light chain variable region, the heavy chain variable region comprises a CDR1 comprising SEQ ID NO:1, a CDR2 comprising SEQ ID NO:2, and a CDR3 comprising SEQ ID NO:3; and The light chain variable region comprises a CDR1 comprising SEQ ID NO:7, a CDR2 comprising SEQ ID NO:8, and a CDR3 comprising SEQ ID NO:
9.
2. the heavy chain variable region comprises a CDR1 consisting of SEQ ID NO:1, a CDR2 consisting of SEQ ID NO:2, and a CDR3 consisting of SEQ ID NO:3; and The nucleic acid molecule of claim 1, wherein the light chain variable region comprises a CDR1 consisting of SEQ ID NO:7, a CDR2 consisting of SEQ ID NO:8, and a CDR3 consisting of SEQ ID NO:
9.
3. the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:4; and The nucleic acid molecule of claim 1 , wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO:
10.
4. the first polypeptide portion comprises a human heavy chain constant region; and The nucleic acid molecule of claim 1 , wherein the second polypeptide portion comprises a human light chain constant region.
5. 5. The nucleic acid molecule of claim 4, wherein the human heavy chain constant region is a human IgG1 Fc domain comprising a Kabat mutation at position 238 that reduces binding to Fc-gamma-receptors (FcγR), where proline 238 (P238) is replaced by an amino acid selected from the group consisting of lysine, serine, alanine, arginine and tryptophan, and wherein the antibody or antigen binding site thereof has reduced FcγR binding.
6. The nucleic acid molecule of claim 5 , wherein the substituted amino acid is lysine.
7. The nucleic acid molecule of claim 6, wherein the Fc domain comprises the amino acid sequence of SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, or SEQ ID NO:
29.
8. the heavy chain variable region comprises a CDR1 consisting of SEQ ID NO:1, a CDR2 consisting of SEQ ID NO:2, and a CDR3 consisting of SEQ ID NO:3; and The nucleic acid molecule of claim 5, wherein the light chain variable region comprises a CDR1 consisting of SEQ ID NO:7, a CDR2 consisting of SEQ ID NO:8, and a CDR3 consisting of SEQ ID NO:
9.
9. the heavy chain variable region comprises a CDR1 consisting of SEQ ID NO:1, a CDR2 consisting of SEQ ID NO:2, and a CDR3 consisting of SEQ ID NO:3; and 7. The nucleic acid molecule of claim 6, wherein the light chain variable region comprises a CDR1 consisting of SEQ ID NO:7, a CDR2 consisting of SEQ ID NO:8, and a CDR3 consisting of SEQ ID NO:
9.
10. the heavy chain variable region comprises a CDR1 consisting of SEQ ID NO:1, a CDR2 consisting of SEQ ID NO:2, and a CDR3 consisting of SEQ ID NO:3; and 6. The nucleic acid molecule of claim 5, wherein the light chain variable region comprises a CDR1 consisting of SEQ ID NO:7, a CDR2 consisting of SEQ ID NO:8, and a CDR3 consisting of SEQ ID NO:
9.
11. The nucleic acid molecule of claim 10, wherein the human IgG1 Fc domain comprises the amino acid sequence of SEQ ID NO:22 or SEQ ID NO:
23.
12. the first polypeptide portion comprises an amino acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:30 and SEQ ID NO:31; and The nucleic acid molecule of claim 1 , wherein the second polypeptide portion comprises the amino acid sequence of SEQ ID NO:
11.
13. the first polypeptide portion comprises the amino acid sequence of SEQ ID NO:5; and The nucleic acid molecule of claim 1 , wherein the second polypeptide portion comprises the amino acid sequence of SEQ ID NO:
11.
14. The nucleic acid molecule according to any one of claims 1 to 3, wherein the antigen-binding site is an scFv-Fc.
15. The nucleic acid molecule of any one of claims 1 to 13, wherein the isolated antibody or antigen-binding portion thereof is humanized.
16. The nucleic acid molecule according to any one of claims 1 to 13, wherein the antibody or antigen-binding portion thereof is linked to a second functional moiety having a binding specificity different from that of the antibody or antigen-binding portion thereof.
17. An expression vector comprising the nucleic acid molecule according to any one of claims 1 to 16.
18. A cell transformed with the expression vector described in claim 17.
19. A cell transformed with a nucleic acid molecule according to any one of claims 1 to 16.
20. 1. An in vitro method for preparing an anti-human CD40 antibody or an antigen-binding portion thereof, comprising: a) expressing the antibody or an antigen-binding portion thereof in a cell according to claim 19; and b) isolating said antibody or an antigen-binding portion thereof from said cell.
21. a) an antibody or antigen-binding portion thereof that specifically binds to human CD40; and b) a pharma- ceutical composition comprising a pharma- ceutical acceptable carrier comprising water, saline, phosphate buffered saline, dextrose, glycerol, ethanol, and any combination thereof; wherein the antibody or antigen binding site comprises a first polypeptide site comprising a heavy chain variable region and a second polypeptide site comprising a light chain variable region, and wherein the antibody or antigen binding site comprises: (1) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:4, and the light chain variable region comprises the amino acid sequence of SEQ ID NO:10; (2) the first polypeptide portion comprises an amino acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:30, and SEQ ID NO:31, and the second polypeptide portion comprises the amino acid sequence of SEQ ID NO:11; (3) the first polypeptide portion comprises the amino acid sequence of SEQ ID NO:5, and the second polypeptide portion comprises the amino acid sequence of SEQ ID NO:11; or (4) the first polypeptide portion comprises the amino acid sequence of SEQ ID NO:6, and the second polypeptide portion comprises the amino acid sequence of SEQ ID NO:11; Pharmaceutical compositions.
22. An antibody or antigen-binding site that: (1) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:4, and the light chain variable region comprises the amino acid sequence of SEQ ID NO:10; (2) the first polypeptide portion comprises the amino acid sequence of SEQ ID NO:5, and the second polypeptide portion comprises the amino acid sequence of SEQ ID NO:11; or (3) the first polypeptide portion comprises the amino acid sequence of SEQ ID NO:6, and the second polypeptide portion comprises the amino acid sequence of SEQ ID NO:11; 22. The pharmaceutical composition of claim 21.
23. 22. The pharmaceutical composition of claim 21, wherein the antibody or antigen-binding site comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:4, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:
10.
24. 22. The pharmaceutical composition of claim 21, wherein the antibody or antigen binding site comprises a first polypeptide site comprising the amino acid sequence of SEQ ID NO:5, and a second polypeptide site comprising the amino acid sequence of SEQ ID NO:
11.
25. a) an antibody or antigen-binding portion thereof that specifically binds to human CD40; and b) a pharma- ceutical acceptable carrier comprising water, saline, phosphate buffered saline, dextrose, glycerol, ethanol and any combination thereof, for use in treating or preventing an immune response, an autoimmune disease, or an inflammatory disease in a subject, comprising: wherein the antibody or antigen binding site comprises a first polypeptide site comprising a heavy chain variable region and a second polypeptide site comprising a light chain variable region, and wherein the antibody or antigen binding site comprises: (1) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:4, and the light chain variable region comprises the amino acid sequence of SEQ ID NO:10; (2) the first polypeptide portion comprises an amino acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:30, and SEQ ID NO:31, and the second polypeptide portion comprises the amino acid sequence of SEQ ID NO:11; (3) the first polypeptide portion comprises the amino acid sequence of SEQ ID NO:5, and the second polypeptide portion comprises the amino acid sequence of SEQ ID NO:11; or (4) the first polypeptide portion comprises the amino acid sequence of SEQ ID NO:6, and the second polypeptide portion comprises the amino acid sequence of SEQ ID NO:11; composition.
26. 26. The composition of claim 25, wherein the antibody or antigen-binding site comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:4, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:
10.
27. 26. The composition of claim 25, wherein the antibody or antigen-binding site comprises a first polypeptide site comprising the amino acid sequence of SEQ ID NO:5, and a second polypeptide site comprising the amino acid sequence of SEQ ID NO:
11.
28. 28. The composition of any one of claims 25 to 27, wherein the subject has a disease selected from the group consisting of Addison's disease, allergies, anaphylaxis, ankylosing spondylitis, asthma, arteriosclerosis, atopic allergies, autoimmune diseases of the ear, autoimmune diseases of the eye, autoimmune hepatitis, autoimmune parotitis, bronchial asthma, coronary heart disease, Crohn's disease, diabetes, epididymitis, glomerulonephritis, Graves' disease, Guillain-Barre syndrome, Hashimoto's disease, hemolytic anemia, idiopathic thrombocytopenic purpura, inflammatory bowel disease, immune response to a genetically modified drug, lupus nephritis, systemic lupus erythematosus, multiple sclerosis, myasthenia gravis, pemphigus, psoriasis, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome, spondyloarthropathy, thyroiditis, transplant rejection, vasculitis, and ulcerative colitis.
Citation Information
Patent Citations
Anti-CD40 antibodies and their use
JP2018520654A
Antibodies against cd40 with enhanced agonist activity
JP2018526977A
Antibodies against cd40
JP2018526978A
Anti-CD40 antibodies and uses thereof
WO2016028810A1
